Law360, New York (May 29, 2009) -- An appellate court has dismissed a $70 million lawsuit accusing Abbott Laboratories of cheating a Cayman Islands-based investment firm out of royalties when the pharmaceutical company stopped developing the ZoMaxx stent, sending the dispute into arbitration.
Judge Shira A. Scheindlin of the U.S. Court of Appeals for the Second Circuit ruled Wednesday that Abbott can compel Cayman Islands-based investment firm Birmingham Associates Ltd. to arbitrate the...


